Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
Adverse events will be closely watched when full data are reported.
Crunch time approaches for UroGen.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Conference activity picks up, with the big one – ASCO – at the end of the month.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.